A 2016 article (which may have been already shared in this thread) when the company was not known to many and there was no noise around. Something interesting to note -
As Laurus expands manufacturing, Chava and Chereddi say its chemistry expertise and commitment to quality are registering in the market. Bruno agrees, pointing to a flagship project.
"To deal with Gilead, they must be doing something right,” Bruno says. “The Gilead drugs are not trivial chemistry. Gilead doesn’t make products that every person in the world can do easily. But Laurus seems to be able to do it.”
https://cen.acs.org/articles/94/i15/CEN-profiles-Laurus-Labs-upping.html
“Our ability to attract NCE work comes from our ability to transform medicinal chemistry processes in early discovery to robust processes when the candidate is moved to later stages of development,” Chava says. Intellectual property generated in process development at Laurus is transferred back to the project sponsor, he says. “One of the key decisions we took is that we will not infringe on patents. Not even for generics.”
This stand of the company seems to give lot of comfort to the innovators, as one of the main concern today is about IP infringement
Majority stake in Laurus Labs was acquired by Aptuit Inc, USA, a pharma service provider during 2007 and thereafter the company was named as Aptuit Laurus Private Limited.
When Laurus Labs was came up with IPO in 2016, Aptuit Inc exited
Later it seems that Aptuit Inc, USA was acquired by German Pharma Company, Evotec somewhere during 2017
Interestingly, Swizz pharma company Lonza had eyed a majority stake in Laurus Aptuit
PS: just tracing a bit of history. Many of you would have already known. May be deleted, if found not adding any value